TCEA1 Suppresses Acute Promyelocytic Leukemia by Upregulating C/EBPε and IRF8 Authors: Taomei Yang, Yonghu Wan, Chunwei Chu, Xiangyun Chen Published: 2026 ABSTRACT We previously showed that TCEA1 deficiency in myeloid cells promotes proliferation, impairs differentiation and inhibits apoptosis, but its role and underlying mechanism in acute myeloid leukemia (AML) are unknown. Here, in NB-4 cells, an M3 subtype of AML, TCEA1 overexpression suppressed proliferation (p < 0.001), induced S-phase arrest (from 35.35% to 19.47%, p < 0.001), increased apoptosis (from 10.37% to 23.5%, p < 0.001), and promoted differentiation. Mechanistically, TCEA1 overexpression upregulated C/EBPε and IRF8 at the mRNA and protein levels; conversely, TCEA1 knockdown downregulated both. Rescue experiments in TCEA1 knockdown 32Dcl3 cells showed that ectopic C/EBPε or IRF8 reversed the uncontrolled proliferation, blocked apoptosis, and impaired differentiation. In xenograft mouse models, TCEA1 overexpression reduced leukemic infiltration in the bone marrow, spleen, and liver; extended overall survival; and elevated C/EBPε and IRF8 expression in vivo. Analysis of public APL datasets revealed that high TCEA1 expression is associated with a favorable prognosis (HR = 0.43, 95% CI: 0.2–0.93, logrank p = 0.028). Collectively, our findings demonstrate that TCEA1 suppresses proliferation, promotes apoptosis and differentiation, and attenuates disease progression by upregulating C/EBPε and IRF8, positioning this regulatory mechanism as a potential therapeutic target and prognostic biomarker for this disease. 1. Introduction Acute myelogenous leukemia (AML) is an aggressive hematologic malignancy characterized by the accumulation of immature myeloid blasts [1,2], arising from coordinated disruptions in differentiation, apoptosis, and proliferation [3,4,5]. Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML) defined by the t(15;17) translocation and the PML–RARA fusion oncoprotein, which blocks myeloid differentiation at the promyelocytic stage and confers apoptosis resistance, thereby driving leukemogenesis. The introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has transformed APL into a curable leukemia, yet early mortality and drug resistance remain significant challenges, highlighting a limitation of current therapies and underscoring the need for novel therapeutic targets and a deeper understanding of leukemogenesis. Transcriptional dysregulation is a prominent feature observed in APL [6,7,8,9,10], with growing evidence implicating aberrant transcription elongation in the misregulation of key hematopoietic transcription factors that control myeloid development [11,12,13,14,15]. The transcription elongation factor TCEA1 (TFIIS) facilitates RNA polymerase II progression through arrest sites, thereby ensuring productive transcription elongation [16,17,18,19]. Our previous functional screen identified TCEA1 as a critical regulator of myelopoiesis, with its knockdown in myeloid precursors leading to uncontrolled proliferation, blocked differentiation, and impaired apoptosis [20], hallmarks of hematopoietic malignancies. Bioinformatic analysis further revealed decreased TCEA1 expression in lymphoma samples [20], raising the possibility that its dysfunction may extend to broader hematopoietic malignancies. CCAAT/enhancer-binding protein epsilon (C/EBPε) and interferon regulatory factor 8 (IRF8) are two pivotal transcription factors governing myeloid differentiation. C/EBPε is essential for terminal granulocytic differentiation, cell cycle arrest, and functional maturation [21,22,23]. C/EBPε regulates the transition from the promyelocytic stage to the myelocytic stage of neutrophil development and is indispensable for secondary and tertiary granule formation [24,25,26], as its deficiency leads to a block in neutrophil maturation. In APL, PML–RARA inhibits C/EBPε expression, whereas ATRA induces C/EBPε expression [8,27]. IRF8 acts as a negative regulator of proliferation and is frequently downregulated in AML; its loss results in uncontrolled proliferation and predisposes to leukemic transformation [7,28,29,30]. In APL, IRF8 acts as a tumor suppressor, and its downregulation by PML–RARA accelerates disease progression [7]. Notably, although ATRA and ATO are effective in APL, they fail to derepress IRF8, leaving this key transcription factor persistently suppressed [31]. Interestingly, public datasets analysis suggested that TCEA1 knockdown could alter the expression of these factors [20], but a direct link in leukemia was unexplored. Given these observations, we hypothesized that TCEA1 suppresses leukemic progression by regulating the expression of C/EBPε and IRF8, thereby inhibiting proliferation and promoting differentiation and apoptosis. To test this hypothesis, we established a stable TCEA1 overexpressing NB4 cell line (NB4-TCEA1). In vitro, TCEA1 overexpression significantly suppressed proliferation, induced apoptosis, and promoted granulocytic differentiation. Mechanistically, TCEA1 overexpression upregulated the expression of C/EBPε and IRF8, whereas TCEA1 knockdown in 32Dcl3 downregulated these transcription factors, suggesting that TCEA1 expression is critical for maintaining C/EBPε and IRF8 levels. Importantly, rescue experiments in TCEA1 knockdown 32Dcl3 cells revealed that forced expression of either C/EBPε or IRF8 not only restored their own expression but also reversed the hyperproliferative phenotype and rescued the differentiation and apoptosis defects caused by TCEA1 loss. To further validate these findings in vivo, we established a mouse xenograft model using NB4-TCEA1 cells. TCEA1 overexpression prolonged mouse survival, attenuated body weight loss, and reduced leukemic infiltration in the peripheral blood, liver, and spleen. Consistent with the in vitro observations, elevated expression of C/EBPε and IRF8 was detected in the peripheral blood and tissues of NB4-TCEA1 xenograft mice. Additionally, analysis of public APL datasets revealed a significant association between high TCEA1 expression and improved overall survival. Collectively, our results identify TCEA1 as an upstream regulator of C/EBPε and IRF8 that controls proliferation, apoptosis, and differentiation in APL, further demonstrating that TCEA1 overexpression suppresses leukemic progression in vivo and correlates with favorable prognosis in APL patients. 2. Results 2.1. Generation of a TCEA1 Over-Expressing Stable Leukemia Cell Line To investigate the functional role of TCEA1 in human leukemia, we first analyzed TCEA1 expression levels across various leukemia cell lines using the Human Protein Atlas database. The results showed that NB4 cells exhibited a relatively low basal expression of TCEA1 compared with that of other leukemia cell lines (Figure 1A). Using the NB4 cell line, we next generated a stable NB4 cell line overexpressing human TCEA1. Specifically, the full length of the TCEA1 coding sequence was cloned and verified by sequencing. High-titer lentivirus was produced (1.5 × 108 TU/mL for both TCEA1 and control viruses). Following transduction and puromycin selection, a population exhibiting strong green fluorescence was visualized under fluorescence microscopy (Figure 1B). Overexpression of TCEA1 was further confirmed at the molecular level by qPCR and at the protein level by Western blot analysis (Figure 1C,D). Collectively, these data confirm the successful generation of a stable NB4 leukemia cell line with a high level of TCEA1 expression compared with that of NB4 control cells, providing a critical tool for subsequent functional studies. 2.2. TCEA1 Overexpression Inhibits Proliferative Capacity of Leukemia Cells To assess the effect of TCEA1 on leukemia cell proliferation, we performed CCK-8 assays. NB4 control and NB4-TCEA1 cells were plated at equal densities and analyzed on days 1, 3, 5, and 7, using the same time points as in our loss-of-function experiments [20] to allow direct phenotypic cross-validation between the gain- and loss-of-function models. Overexpression of TCEA1 significantly reduced the viability and proliferation rate of the NB4 cells compared with that of the control cells (Figure 2A). To determine whether this growth inhibition was associated with cell cycle alterations, we analyzed the cell cycle distribution via propidium iodide staining and flow cytometry. As shown in Figure 2B, NB4-TCEA1 cells exhibited a marked decrease in the percentage of cells in the S phase (19.47% ± 0.11%) compared with that in the NB4 control cells (35.50% ± 0.88%), p < 0.001. These results, together with the proliferation data (Figure 2A), indicate that TCEA1 functions as a negative regulator of cell proliferation in APL by impeding cell cycle progression. 2.3. TCEA1 Overexpression Promotes Apoptosis and Differentiation In Vitro To further investigate the role of TCEA1 in myeloid cell apoptosis, we assessed the apoptotic rate using Annexin V-APC/7-AAD double staining, followed by flow cytometric analysis. In addition to its inhibitory effect on proliferation, TCEA1 overexpression significantly enhanced apoptosis in NB4 cells. Flow cytometry analysis revealed a marked increase in the percentage of Annexin V positive apoptotic cells in the NB4-TCEA1 cells compared with that in the controls. Specifically, the apoptotic rate in the NB4 control cells was 10.37% ± 0.66%, whereas it increased to 23.50% ± 0.53% in the NB4-TCEA1 cells, p < 0.001. Concurrently, the proportion of dead cells increased from 6.65% ± 0.40% to 16.31% ± 2.30%, p < 0.01 (Figure 3A). To determine whether TCEA1 also influences leukemic differentiation, we assessed morphological changes and the expression of granule protein genes during all-trans retinoic acid (ATRA) treatment. Quantitative PCR analysis revealed that TCEA1 overexpression altered the expression profile of granule protein genes. Compared with control cells, NB4-TCEA1 cells showed a decreased expression of primary granule proteins myeloperoxidase (MPO), proteinase 3 (PRTN3), and neutrophil elastase (ELANE) and significantly increased expression of the secondary granule protein lactotransferrin (LTF), as well as the tertiary granule proteins matrix metalloproteinase 9 (MMP9) and cysteine-rich secretory protein 3 (CRISP3) granule protein transcripts (Figure 3B). All changes were statistically significant (p < 0.05, p < 0.01). Morphological analysis further demonstrated that control NB4 cells exhibited a typical primitive myeloid morphology characterized by large nuclei, a high nuclear-to-cytoplasmic ratio (0.95 ± 0.07), and round or oval shapes. In contrast, NB4-TCEA1 cells exhibited differentiation features: reduced nuclear-to-cytoplasmic ratio (0.88 ± 0.13, p < 0.001), smaller area (60.75 ± 15.40 µm2), lower circularity (0.67 ± 0.14, p < 0.001), and nuclear segmentation (Figure 3C). These morphological findings, together with the molecular data (Figure 3B), confirm that TCEA1 promotes APL cell differentiation. Collectively, these data indicate that TCEA1 not only triggers apoptosis but also alleviates the differentiation block, thereby promoting both differentiation and apoptosis in this APL cell model. 2.4. TCEA1 Positively Regulates C/EBPε and IRF8 Expression Guided by bioinformatic analyses linking diminished TCEA1 expression to reduced levels of the myeloid transcription factors C/EBPε and IRF8 [20], we next examined whether TCEA1 overexpression could conversely enhance their expression. Indeed, we found that enforced TCEA1 expression in NB4 cells significantly upregulated both C/EBPε and IRF8 mRNA levels (Figure 4A). Consistent with the transcriptional data, Western blot analysis confirmed a concomitant increase in C/EBPε and IRF8 protein abundance (Figure 4B). To further validate these results, we validated the knockdown efficiency of four TCEA1 siRNAs in 32Dcl3 cells and selected the most effective siRNA-676, which was designated as siTCEA1 for subsequent experiments (Figure 4C). In 32Dcl3 cells with TCEA1 knockdown, Western blot analysis demonstrated markedly reduced protein levels of C/EBPε (Figure 4D, lane 2) and IRF8 (Figure 4E, lane 2) relative to those of the control cells (lane 1). To determine whether the reduction of C/EBPε and IRF8 was specifically due to TCEA1 loss, rescue experiments were performed by reintroducing C/EBPε or IRF8 expression vectors into TCEA1 knockdown cells. Notably, ectopic expression of C/EBPε (Figure 4D, lane 4) and IRF8 (Figure 4E, lane 4) was successfully restored. These reciprocal findings indicate that TCEA1 acts as a positive regulator of C/EBPε and IRF8, establishing TCEA1 as a key determinant of these critical granulocytic transcription factors. 2.5. TCEA1 Suppresses Proliferation and Promotes Apoptosis and Differentiation of Granulocytic Cells Through C/EBPε and IRF8 To determine whether C/EBPε and IRF8 mediate the functional effects of TCEA1, we performed rescue experiments in TCEA1 knockdown 32Dcl3 cells by overexpressing C/EBPε or IRF8, with the corresponding empty vector as a control. The expression of C/EBPε or IRF8 was confirmed prior to preforming the functional assays (Figure 4D,E). As shown, rescue expression of either C/EBPε or IRF8 significantly suppressed the hyperproliferative phenotype induced by TCEA1 knockdown when cells were cultured in interleukin-3 (IL-3) containing medium, as assessed by CCK-8 at days 1, 3, 5, and 7, p < 0.001 (Figure 5A). Similarly, under granulocyte colony-stimulating factor (G-CSF)-induced differentiation conditions, the cell viability significantly downregulated upon expression of either C/EBPε or IRF8, p < 0.001 (Figure 5B). Cell cycle analysis further revealed that, compared with the siTCEA1 + Vector control, re-expression of either C/EBPε or IRF8 significantly reduced the proportion of cells in the S phase, under both IL-3 and G-CSF conditions (p < 0.001; Figure 5C and 5D, respectively). Apoptosis analysis (Figure 6A,B) showed that forced expression of C/EBPε or IRF8 in TCEA1 knockdown cells markedly increased the percentage of apoptotic cells compared with that of the vector control under both culture conditions (p < 0.01, p < 0.001). We next examined whether re-expression of C/EBPε or IRF8 could rescue the differentiation arrest induced by TCEA1 loss, as previously characterized [20]. Results (Figure 6C) showed that forced expression of either C/EBPε or IRF8 in TCEA1 knockdown cells significantly downregulated early granule proteins (MPO, PRTN3, ELANE) and upregulated secondary (LTF) and tertiary (MMP9, CRISP3) granule proteins (p < 0.01). These results demonstrate that C/EBPε and IRF8 act downstream of TCEA1 to promote granulocytic differentiation and apoptosis while inhibiting proliferation. 2.6. TCEA1 Suppresses Leukemia Progression In Vivo To evaluate the in vivo role of TCEA1 in myeloid leukemia progression, we established a xenograft mouse model. Recipient mice received a sublethal dose of total-body irradiation prior to cell injection to transiently suppress their residual innate immune activity and provide a permissive engraftment window for the injected cells. Subsequently, NB4 control cells or NB4-TCEA1 cells were intravenously injected into the irradiated mice to establish an APL xenograft model. 2.6.1. Survival Analysis Kaplan–Meier survival analysis of pooled data from three independent experiments (total n = 18 per group) revealed that mice bearing NB4-TCEA1 cells exhibited a significantly prolonged overall survival, with the median survival being 25 days in the control group, while it was not reached within the observation period of 28 days in the NB4-TCEA1 group (Figure 7A, log-rank test, p = 0.04). Consistent with this, the percentage of body weight loss was significantly reduced in the TCEA1 overexpressing group compared to the controls (Figure 7B, p < 0.05). 2.6.2. Leukemia Cell Burden in Peripheral Blood At day 21 post-inoculation, flow cytometric analysis was performed to assess the proportion of GFP+CD33+ leukemic cells in the peripheral blood. The TCEA1 overexpressing group showed a significantly lower proportion (15.9% ± 0.2%) compared to that of the control group (26.3% ± 0.6%; **, p < 0.01; Figure 7C). Collectively, these results indicate that TCEA1 overexpression reduces leukemic burden in peripheral blood. 2.6.3. Inhibition of Organ Infiltration by TCEA1 Histopathological analysis was performed to assess extramedullary infiltration. Macroscopically, neither group exhibited significant hepatosplenomegaly. Hematoxylin and eosin (HE) staining of liver and spleen tissues was performed to assess the impact of TCEA1 on leukemic cell infiltration. In the spleen, tissue from control mice showed extensive architectural disruption by dense leukemic infiltrates. In contrast, spleens from the TCEA1 overexpressing group displayed preserved structure, with markedly fewer infiltrating cells (Figure 8A). A parallel effect was observed in the liver. Control mice exhibited obvious leukemic cell infiltrates, which were substantially diminished in the TCEA1 overexpressing group (Figure 8B). Collectively, these findings demonstrate that TCEA1 effectively inhibits the tissue infiltration and dissemination of leukemia cells to major organs. This suppression of extramedullary infiltration complements its previously demonstrated effects on reducing peripheral blood tumor burden, underscoring its multifaceted role in attenuating leukemia progression in vivo. 2.6.4. TCEA1 Upregulates C/EBPε and IRF8 Expression In Vivo Having established that TCEA1 overexpression upregulates the key myeloid transcription factors C/EBPε and IRF8 in vitro (Figure 4), we next investigated whether this program is engaged in vivo and examined its relevance to leukemic dissemination. To elucidate the molecular mechanism underlying TCEA1 function in vivo, we examined C/EBPε and IRF8 expression levels in tissues from xenograft mice. Quantitative PCR analysis of peripheral blood leukocytes revealed significantly elevated mRNA levels of both transcription factors in the TCEA1 overexpressing group compared to that in the controls (Figure 9A). Consistently, Western blot analysis confirmed increased protein levels of C/EBPε and IRF8 in both liver and spleen tissues from NB4-TCEA1 mice (Figure 9B,C). These in vivo findings are consistent with our in vitro mechanistic studies, further validating that TCEA1 exerts its biological functions by upregulating C/EBPε and IRF8 expression. 2.7. High TCEA1 Expression Correlates with Favorable Prognosis in APL Patients To further explore the clinical relevance of our findings, we next examined the correlation between TCEA1 expression and patient outcomes using the Kaplan–Meier Plotter online tool. A total of 67 APL patients (FAB M3 subtype) were included in the analysis. Based on the optimal cutoff value of 3975, 37 patients were classified into the high-TCEA1 expression group and 30 into the low-expression group. High-TCEA1 expression was associated with a lower risk of death (HR = 0.43, 95% CI: 0.2–0.93, logrank p = 0.028, Figure 9D). Kaplan–Meier analysis revealed that the upper quartile survival time was 38.7 months in the high-expression group compared with only 0.5 months in the low-expression group. These findings align with our experimental data showing that TCEA1 suppresses proliferation and promotes differentiation in APL cells. 3. Discussion This study establishes TCEA1 as a critical regulator that supports proper myeloid differentiation, induces apoptosis, and inhibits leukemic proliferation in human APL. Using the NB4 cell line, which we found to exhibit low basal TCEA1 expression and which represents the M3 subtype of AML, we demonstrate that elevating TCEA1 levels suppresses the malignant phenotype both in vitro and in vivo. In particular, TCEA1 overexpression inhibits proliferation, induces differentiation, and promotes apoptosis. Differentiation blockade in APL is associated with dysregulated expression of key myeloid transcription factors, including C/EBPε and IRF8, which are essential for granulocytic maturation [9,27,31]. Thereby, our work positions TCEA1 as a guardian of the transcriptional programs required for myeloid maturation. Mechanistically, this function is mediated through its positive regulation of the transcription factors C/EBPε and IRF8. As is known, C/EBPε is a master regulator of terminal granulopoiesis, and its deficiency leads to myelodysplasia and blocks differentiation [21,27,32,33]. Consistent with this, C/EBPε expression is known to be suppressed in APL. ATRA, a differentiating agent to which APL is particularly sensitive, induces APL differentiation specifically through upregulating C/EBPε [27]. IRF8 acts as a brake on proliferation, and its loss is associated with APL [7,28,34]. However, ATRA and ATO are unable to relieve PML/RARα-mediated repression of IRF8, leaving its expression refractory to current differentiation therapies [31]. Using complementary gain- and loss-of-function approaches, we showed that TCEA1 positively regulates C/EBPε and IRF8 expression, as evidenced by upregulation following TCEA1 overexpression and downregulation following its knockdown. Crucially, rescue experiments, in which re-expression of C/EBPε or IRF8 reversed the differentiation arrest, hyperproliferation, and apoptosis defect caused by TCEA1 knockdown, confirm that these transcription factors act as critical downstream mediators of TCEA1′s function. Given that IRF8 activates the pro-apoptotic gene Bax and represses the anti-apoptotic genes Bcl-xL and Bcl-2 in myeloid cells [35,36,37], the increased apoptosis observed upon TCEA1 overexpression is likely mediated through IRF8-dependent regulation of these Bcl-2 family members. Thus, TCEA1 exerts its pro-differentiation, anti-proliferative, and pro-apoptotic effects through positive regulation of C/EBPε and IRF8. Notably, unlike ATRA or ATO, TCEA1 can effectively restore IRF8 expression, which otherwise remains refractory to current therapies, highlighting TCEA1 as a promising target for overcoming differentiation resistance in APL. In interpreting the antiproliferative and pro-apoptotic effects described above, CCK-8 was monitored at the same time points (1, 3, 5, and 7 days) used in our loss-of-function experiments [20], which did not include a dedicated 48 h measurement. At 48 h, TCEA1 overexpression increased the apoptotic rate and the proportion of dead cells (Figure 3A). Because a CCK-8 measurement was not taken at this time point, the reduced signal alone cannot directly distinguish whether it reflects genuine proliferation arrest or is secondary to the increased cell death. However, several lines of evidence indicate that both mechanisms contribute independently. The estimated net reduction in cell expansion at 48 h, derived from the CCK-8 curve, substantially exceeded the increase in either apoptotic or dead cells alone. Moreover, the S-phase fraction decreased markedly at the same time point (Figure 2B), providing an apoptosis-independent confirmation of impaired cell cycle progression. These observations argue that the loss of the CCK-8 signal reflects genuine proliferation arrest, in addition to cell death, and the sustained decrease over the experimental period is best understood as the cumulative outcome of concurrent antiproliferative and pro-apoptotic mechanisms. Consistent with these observations, TCEA1 overexpression in a xenograft model led to a marked reduction in disease burden. This was evidenced by diminished infiltration into the spleen and liver, accompanied by reduced leukemic burden in the peripheral blood. Such suppression of extramedullary dissemination is particularly notable, as it suggests a role for TCEA1 in limiting the invasive potential of leukemic cells. Emerging evidence has established that transcriptional elongation control plays a pivotal role in myeloid lineage commitment and leukemogenesis. In granulocytic differentiation, proper RNA polymerase II (RNAPII) pause–release dynamics are essential for the timely expression of lineage-specific transcription factors [38,39,40,41]. Indeed, RNAPII promoter-proximal pausing is a key regulatory event in transcription, and its dysregulation impairs the precise temporal expression of genes required for cell-fate decisions [40,41,42]. Lineage-specific transcription factors such as C/EBPε and IRF8, which govern granulopoiesis [24,33,43,44,45,46], are subjected to such regulatory control, as their expression must be precisely timed during myelopoiesis. Accordingly, their dysregulation, whether through aberrant transcriptional elongation or other mechanisms, is responsible for differentiation arrest and proliferation promotion. Notably, aberrant elongation control has been implicated in the pathogenesis of other myeloid malignancies, particularly in MLL-rearranged leukemias. An oncogenic principle underlying these leukemias is the pathological hijacking of the RNA polymerase II transcriptional elongation regulation [47,48]. MLL fusion proteins function as aberrant scaffolds that constitutively recruit the Super Elongation Complex (SEC) and its catalytic engine CDK9 to oncogenic loci to drive the sustained expression of leukemogenic drivers such as HOXA9 and MEIS1 [47,48,49,50]. This transcriptional addiction state results in the sustained expression of key hematopoietic regulators, which in turn block differentiation, confer apoptosis resistance, and promote uncontrolled proliferation [50]. In contrast to this oncogenic mechanism in other myeloid malignancies, our findings reveal a distinct role for TCEA1 in APL. Rather than driving leukemogenic gene expression, TCEA1 facilitates the expression of myeloid differentiation-associated transcription factors C/EBPε and IRF8, thereby suppressing APL progression. These findings, together with the established role of TCEA1 in transcriptional elongation [16,17], add a new insight into the understanding of transcriptional regulation in APL, revealing a functional role for TCEA1 in promoting the expression of key transcription factors that govern myeloid differentiation and restrict leukemic progression. Notably, given that IRF8 is refractory to ATRA/ATO [31], TCEA1-mediated upregulation of IRF8 offers a potential therapeutic strategy for resistant APL. Together, these findings position TCEA1 as a functionally unique regulator within the transcriptional elongation network, pointing to its potential as a therapeutic target. Several limitations of this study should be considered. Our functional and mechanistic insights are primarily derived from a gain-of-function model in the NB4 cell line, which represents the M3 subtype of AML. While this provides a valuable proof-of-concept, further validation in a broader panel of APL or other AML cell lines representing non-M3 subtypes, as well as in primary patient-derived samples, is necessary to confirm the generalizability of our findings, and whether TCEA1 plays a similar role in non-M3 AML subtypes remains an open question for future investigation. Additionally, in vivo survival analysis confirmed that TCEA1 overexpression significantly prolonged overall survival, with the median survival not reached in the TCEA1 group within the observation period, compared to a median survival of 25-day in the control group. Because the observation was terminated before the TCEA1 group reached median survival, the true survival benefit may be even greater than that captured here. Therefore, studies with extended observation periods would be valuable to precisely quantify the full extent of survival prolongation and to assess long-term outcomes. With respect to the experimental design, although an irradiation-only control group was not included, sublethal irradiation (3 Gy) in NOD/SCID mice has been shown not to cause mortality over observation periods of 9 weeks and 20 weeks, respectively [51,52], both substantially exceeding the 28-day duration of our experiment. Given that sublethal irradiation alone is insufficient to cause mortality within this timeframe, the survival differences observed between the NB4-control and NB4-TCEA1 groups reflect differential leukemia progression rather than irradiation-related toxicity. Furthermore, our in vitro loss-of-function studies were conducted in murine cells, which, while complementary, do not fully recapitulate the human disease context. Future studies using conditional knockout models will be essential to delineate the physiological role of TCEA1 in normal hematopoiesis and its contribution to leukemogenesis in vivo. Mechanistically, although we have identified C/EBPε and IRF8 as key downstream effectors, the further precise molecular mechanism by which TCEA1 facilitates their transcriptional elongation requires further investigation. Advanced techniques such as precision nuclear run-on sequencing (PRO-seq) and chromatin immunoprecipitation (ChIP) will be critical to determine whether TCEA1 directly binds to and promotes RNA polymerase II processivity at these target loci. Finally, while our bioinformatic analysis using publicly available datasets revealed a significant association between high TCEA1 expression and improved overall survival in APL patients, this correlative finding requires validation in independent, prospectively collected clinical cohorts to fully ascertain its prognostic and translational potential. In conclusion, our study establishes TCEA1 as a critical regulator of myeloid proliferation, differentiation, and apoptosis in APL. We demonstrate that TCEA1 functions by upregulating the expression of the key transcription factors C/EBPε and IRF8, thereby promoting granulocytic maturation and restraining leukemic phenotypes. Complemented by bioinformatic data linking TCEA1 expression to favorable clinical outcomes, this work identifies TCEA1 as an important modulator of myeloid homeostasis whose dysregulation contributes to APL pathogenesis, establishing it as a potential therapeutic target. 4. Materials and Methods 4.1. Cell Culture The human acute promyelocytic leukemia cell line NB4 was purchased from Procell (cat. no. CL-0676, Wuhan, China) and was maintained in NB4-specific medium (cat. no. ZM0553, Zqxzbio, Shanghai, China), consisting of RPMI1640 supplemented with 10% fetal bovine serum (FBS) and 1% penicillin–streptomycin (100 U/mL penicillin, 100 μg/mL streptomycin). For differentiation studies, cells were treated with 1 µM all-trans retinoic acid (ATRA, cat. no. HY-14649, MedChemExpress, Monmouth Junction, NJ, USA). The human embryonic kidney 293 cells expressing the SV40 large T antigen (HEK293T) packaging cell line was cultured in Dulbecco’s Modified Eagle Medium (cat. no. 11965092, Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (cat. no. 16000044, Thermo Fisher Scientific). 32Dcl3, a murine myeloid progenitor cell line that proliferates in an IL-3-dependent manner and differentiates into granulocytes upon G-CSF stimulation, was cultured in growth medium containing IL-3 (2 ng/mL, cat. no. 213-13, PeproTech, Cranbury, NJ, USA) and differentiation medium containing G-CSF (50 ng/mL, cat. no. 250-05, PeproTech), as described previously [20]. All cell lines were incubated at 37 °C in a humidified atmosphere of 5% CO2. 4.2. Generation of TCEA1-Overexpressing Stable Cell Line A lentiviral system was employed to generate NB4 cells stably overexpressing human TCEA1. The full-length human TCEA1 coding sequence was cloned into the pHBLV-CMV-MCS-EF1-ZsGreen-T2A-puro lentiviral vector (cat. no. LV083, Hanbio Biotechnology, Shanghai, China). The recombinant plasmid, along with the packaging plasmids psPAX2 and pMD2.G, was co-transfected into HEK293T cells using Lipofiter™ transfection reagent (cat. no. 11668091, Thermo Fisher Scientific). Viral supernatant was harvested at 48 and 72 h post-transfection, concentrated by ultracentrifugation, and resuspended in a small volume of culture medium. Viral titer was determined on 293T cells and reached 1.5 × 108 transducing units (TU)/mL. For transduction, NB4 cells were incubated with the concentrated TCEA1-overexpressing lentivirus or a control virus (carrying the empty vector) in the presence of polybrene (8 µg/mL, cat. No.TR1003, Sigma-Aldrich, St. Louis, MO, USA). At 24 h post-transduction, the medium was replaced with fresh complete medium. Stable polyclonal populations were selected with puromycin (1 µg/mL, cat. no. P4512, Sigma-Aldrich) for one week. Successful overexpression was confirmed by visualization of green fluorescence and quantified by qRT–PCR and Western blot analysis of TCEA1 expression. 4.3. Cell Proliferation and Viability Assay Cell proliferation and viability were assessed using the Cell Counting Kit-8 (cat. no. HY-K0301, MedChemExpress LLC, Monmouth Junction, NJ, USA). Cells were seeded in 96-well plates at a density of 5 × 103 cells per well and cultured for 1, 3, 5, and 7 days. To avoid nutrient depletion and medium acidification during the prolonged 7-day culture, 50% of the culture medium was gently removed and replaced with an equal volume of fresh medium every other day. At the indicated time points, 10 µL of CCK-8 reagent was added to each well. After incubation at 37 °C for 2–4 h, the absorbance at 450 nm was measured using a microplate reader (MultiSkan FC, Thermo Fisher Scientific, Waltham, MA, USA). Experiments were performed in triplicate wells and repeated at least three times independently. Data were normalized to the control group at 24 h (set as 100%) to calculate relative proliferation rates. 4.4. Cell Cycle Analysis Cells in the logarithmic growth phase after 48 h of culture were harvested, washed twice with phosphate-buffered saline (PBS), and fixed in 70% ice cold ethanol at 4 °C for 2 h. After fixation, cells were washed with PBS and then resuspended in the staining solution containing PBS, 200 µg/mL RNase A (cat. no. R8020, SOLARBIO, Beijing, China), and 50 µg/mL propidium iodide (PI; cat. no. P4170, Sigma-Aldrich). Cells were incubated in this staining solution at 37 °C for 20 min in the dark. DNA content was analyzed immediately using a flow cytometer (Beckman Coulter, Brea, CA, USA). Cell cycle phase distribution was quantified from the DNA content using Cell Quest software (MultiCycle for Windows 32-bit). 4.5. Cell Apoptosis Assay Cell apoptosis was analyzed by flow cytometry using an annexin V-APC/7-AAD detection kit (cat. no. KGA1106-100, KeyGene Biotech, Nanjing, China), according to the manufacturer’s instructions. Cells cultured for 48 h were harvested, washed with PBS, and resuspended in binding buffer. Cells were stained with APC-conjugated annexin V and 7-AAD in the dark for 15 min at room temperature, diluted with additional buffer, and analyzed immediately by flow cytometry. Viable (annexin V-APC−/7-AAD−), early apoptotic (annexin V-AP+/7-AAD−), and late apoptotic (annexin V-APC+/7-AAD+) populations were quantified (Beckman coulter cytoFLEX). Experiments were performed in triplicate and repeated three times independently. 4.6. Morphologic Analysis In Vitro NB4 and NB4-TCEA1 cells were treated with 1 μM all-trans retinoic acid (ATRA, cat. no. HY-14649, MedChemExpress) or vehicle control (DMSO) for 4 days, changing the 40% medium every day. Cells were harvested, and blood smears were prepared. After air drying, slides were stained with Wright–Giemsa stain solution (cat. no. G1007, Servicebio, Wuhan, China), according to standard protocols. Specifically, slides were stained with Wright’s stain for 1 min, followed by Giemsa stain for 30 s, and then Wright–Giemsa C solution for 2 min, with gentle rinsing using distilled water between each step. Cellular morphology was evaluated by light microscopy (Nikon, Tokyo, Japan), and representative images were captured. Quantitative morphological analysis was performed using ImageJ: for each group, at least 100 cells from three independent experiments were manually delineated to measure cell area (μm2), cell circularity, and nuclear-to-cytoplasmic (N/C) ratio. Differentiation was assessed based on these parameters. 4.7. Quantitative Real-Time PCR Total RNA was extracted using TRIzol reagent (cat.no. R401-01, VAZYME, Nanjing, China)). cDNA was synthesized from 1 µg of RNA using the HiScript II Q RT SuperMix (cat. no. R223-01, Vazyme). Quantitative PCR was performed in triplicate on a Real-Time PCR System (QuantStudio 6) with SYBR Green Master Mix (cat. no. R223-01, Vazyme). Primer sequences are summarized in Supplementary Table S1. 4.8. Western Immunoblots Cells were cultured for 48 h, and protein lysates were extracted from exponentially growing cells using RIPA lysis buffer (cat. no. MA0151, Meilunbio, Dalian, China) supplemented with protease inhibitor cocktail (cat. no. MB12707, Meilunbio). Protein concentrations were determined using a BCA assay (cat. no. G3422, GBCBIO, Guangzhou, China). Equal amounts of protein (30 µg per lane) were separated by SDS-PAGE on 10% gels and transferred to PVDF membranes (cat. no. IPVH00010, Millipore, Burlington, MA, USA). Membranes were blocked with 5% BSA in TBST for 2 h at room temperature and subsequently incubated overnight at 4 °C with primary antibodies diluted in blocking buffer. The following primary antibodies were used: anti-TCEA1 (1:1000, cat. no. 17825-1-AP, Proteintech, Wuhan, China), anti-C/EBPε (1:1000, cat. no. PA5-36094, Thermo Fisher), and anti-IRF8 (1:1000, cat. no. 18977-1-AP, Proteintech,). After washing, membranes were incubated with an HRP-conjugated secondary antibody for 1 h at room temperature. Membranes were then incubated with HRP-conjugated secondary antibodies: goat anti-mouse IgG (H + L)-HRP (1:10,000, cat.no. BA1051, Wuhan Boster Biological Technology, Wuhan, China) and goat anti-rabbit IgG (H+L)-HRP (1:10,000, cat. no. BA1054, Wuhan Boster Biological Technology). Protein bands were visualized using an enhanced chemiluminescence (ECL) luminescent liquid (Super ECL Chemiluminescence Substrate Detection Kit, cat. no. PMK003, BioPM, Beijing, China). The membranes were imaged with a ChemiDoc MP imaging system (Model SH-523, Shenhua Technology, Hangzhou, China). Band intensities were quantified using ImageJ software and normalized to β-actin (1:5000, cat. no. 66009-1-Ig, Proteintech) or GAPDH (1:5000, cat. no. 66009-1-Ig, Proteintech). 4.9. NB4-TCEA1 Xenograft Model All animal procedures were approved by the institutional animal care and use committee of Guizhou University of Traditional Chinese Medicine (approval no. 2025022). The mice (NOD/SCID, 6–8 weeks old, female) were purchased from SPF (Beijing) Biotechnology (Beijing, China). After 5 days of acclimatized, the mice were randomly assigned to two groups: the NB4 control group and the NB4-TCEA1 group. Inclusion criteria for all mice were healthy appearance, normal activity, body weight within ±20%, and absence of any visible abnormalities. The experiment was performed three times independently, with each experiment containing six mice per group. (the NB4 control group and the NB4-TCEA1 group). The mice received a sublethal dose of total body irradiation (3 Gy) [51,52] using Elekta Axesse. Within 24 h post-irradiation, the mice were injected via the tail vein with 1 × 107 NB4-TCEA1 or NB4 control cells in 0.2 mL PBS. Following transplantation, the mice were housed under specific pathogen-free conditions with autoclaved food, water, and bedding. The mice were monitored daily for weight, activity, and signs of illness. The mice were euthanized at defined endpoints or upon meeting humane endpoints. Peripheral blood, spleens, and livers were harvested. 4.10. Analysis of Leukemic Cell Infiltration in Peripheral Blood Peripheral blood was collected from xenograft model mice at day 21 post-inoculation [53]. Red blood cells were lysed using ACK lysis buffer (cat. no. A1049201, Thermo Fisher Scientific). The remaining leukocytes were washed, counted, and resuspended in staining buffer (PBS containing 2% FBS). Cells were incubated with an anti-human CD33 antibody (cat. no. 17425-1-AP, Proteintech) at a predetermined optimal dilution for 30 min at 4 °C in the dark, followed by washing. Cell populations were analyzed on a flow cytometer (cytoFLEX, Beckman coulter). Leukemic cells were identified as GFP+ (from the transduced NB4 cells) and CD33+ (human myeloid marker) double-positive events. The percentage of GFP+CD33+ cells among total live leukocytes was calculated to quantify the level of leukemic cell infiltration in the peripheral blood. 4.11. Pathological and Histological Analysis Liver and spleen tissues were harvested, weighed, and fixed in 4% paraformaldehyde. Following fixation, tissues were dehydrated and embedded in paraffin using an automatic tissue dehydrator (JT-12J, Wuhan Junjie Electronics, Wuhan, China)) and a paraffin embedding machine (JB-P5, Wuhan Junjie Electronics). Xylene (cat. no. 10023418, Sinopharm, Shanghai, China) was used as a clearing agent. Tissue blocks were sectioned at a 4 μm thickness using a pathological microtome (Leica RM 2016, Leica Biosystems, Nussloch, Germany). Sections were mounted onto adhesion slides (PC2-301-16, Meiweide Life Science, Guangzhou, China), dried at 60 °C for 3 h on a tissue drying plate (JK-6, Wuhan Junjie Electronics), then deparaffinized in xylene and rehydrated through a graded ethanol series. Staining was performed with Mayer’s hematoxylin (cat. no. H9627, Sigma) for 5 min, followed by 1% alcoholic eosin (cat. no. 71014460, Sinopharm) for 2 min. After dehydration and clearing, sections were mounted with neutral balsam (cat. no. 20200237, Nanchang Yulu Experimental Equipment, Nanchang, China). Images were captured using a light microscope (Nikon ECLIPSE Ci-L) equipped with a digital camera (Nikon Fi3, Nikon Corporation, Tokyo, Japan). Leukemic infiltration was assessed by light microscopy based on the morphological identification of NB4-like cells (large nuclei, high nuclear-to-cytoplasmic ratio, fine chromatin, and prominent nucleoli) in hematoxylin–eosin-stained liver and spleen sections. Two independent observers blinded to the groups performed the evaluation. Representative images were captured to illustrate the presence or absence of infiltrating blasts. 4.12. Analysis of APL Patient Cohorts The clinical relevance of TCEA1 in APL was evaluated using the Kaplan–Meier Plotter online tool (https://kmplot.com/), which integrates gene expression and survival data from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) [29,30]. The analysis was restricted to patients with the FAB M3 subtype (APL). Patients were dichotomized into high- and low-expression groups using the platform’s optimal cutoff algorithm, which identifies the expression threshold that maximizes the survival difference. The optimal cutoff value was 3975. Patients with TCEA1 expression above 3975 were assigned to the high-expression group, and those below or equal to 3975 to the low-expression group. Kaplan–Meier survival curves were generated, and the log-rank test was used to compare overall survival between the two groups. The hazard ratio (HR) with the 95% confidence interval (CI) was calculated using the Cox proportional hazards regression model. 4.13. Statistical Analysis Data are presented as mean ± SD. Western blot band intensities were quantified using ImageJ software and normalized to the loading control. Comparisons between the two groups were made using a two-tailed, unpaired Student’s t-test. Survival curves were analyzed by the log-rank test. p values < 0.05 were considered significant. Analyses were performed using GraphPad Prism 11.